Drug
Sep 225289
Sep 225289: highest development phase Phase 2, developed by Sumitomo Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| SEP-225289 NCT01692782 | Phase 2 | Adult Attention Deficit Hyperactivity Disorder |
Latest
No recent events.
Follow Sep 225289 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.